Prevalence of Obesity in Patients with Psoriasis: Results of the National Study PsoHealth3

Abstract

Background: Psoriasis is frequently associated with obesity which possibly contributes to reduced treatment response. Objectives: Assessment of the prevalence of obesity in patients with psoriasis in Germany 2013/2014. Patients and Methods: The frequency of overweight and obesity was assessed by the body mass index (BMI) and evaluated according to the severity of psoriasis [Psoriasis Area and Severity Index (PASI)]. Results: This national, cross-sectional survey involved 83 dermatological practices and outpatient clinics, including 1,265 patients (mean age 52 years; 43.4% female). The BMI of patients with psoriasis in 2013/2014 was found to be 28.0 and therefore was significantly higher compared to that of patients with psoriasis in 2007 with a BMI of 26.9 as well as compared to the normal population in 2013 with an overall BMI of 25.9. Conclusions: The prevalence of obesity in patients with psoriasis is higher than in the normal population. The trend towards a higher BMI in patients with psoriasis continues over time.

The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE)

“…Although it is well known that obesity is closely related to psoriasis in western populations81314, the mean BMI of 23.9±3.5 kg/m 2 noted in our study was considerably lower than the mean BMI of 28.0 kg/m 2 observed in western populations13. In addition, Kim and Lee15 reported no statistical difference in BMI between the patients with psoriasis and a control group in one study of a Korean population.…”

Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A Critically Appraised Topic

“…Obesity, defined as BMI > 30 kg m −2 , is a state of excessive fat accumulation that presents a rising public health challenge and is strongly associated with both psoriasis and PsA . Obesity is more prevalent among individuals with psoriasis or PsA (30–40%) than in the general population (15–20%), and the risk of obesity is higher in patients with severe psoriasis [odds ratio (OR) 2·23] compared with those with mild phenotypes (OR 1·46) . Longitudinal population‐based studies suggest a causal role for obesity in psoriasis and PsA onset (adjusted risk ratios 1·87 and 3·12, respectively), and that obesity drives greater disease severity and reduces the probability of successful treatment with biologic agents by up to 50% .…”

Increased risk of psoriasis in subjects with abdominal obesity: A nationwide population‐based study

“…Psoriasis is a chronic inflammatory skin disorder related to T‐helper (Th)1 and Th17 cells with an incidence of approximately 1–3% in the general population . Psoriasis can involve the skin, nails and joints, and is also known to be associated with a variety of systemic comorbidities, such as cardiovascular disorders, stroke, high blood pressure, hyperlipidemia, diabetic mellitus, metabolic syndrome and obesity …”